1
|
Sušić L, Maričić L, Šahinović I, Kralik K, Klobučar L, Ćosić M, Sušić T, Vincelj J, Burić A, Burić M, Lukić M. The Relationship of Left Ventricular Diastolic Dysfunction and Asymmetrical Dimethylarginine as a Biomarker of Endothelial Dysfunction with Cardiovascular Risk Assessed by Systematic Coronary Risk Evaluation2 Algorithm and Heart Failure-A Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:4433. [PMID: 36901443 PMCID: PMC10001866 DOI: 10.3390/ijerph20054433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 02/21/2023] [Accepted: 02/27/2023] [Indexed: 06/18/2023]
Abstract
Background: Cardiovascular (CV) risk factors, causing endothelial dysfunction (ED) and left ventricular diastolic dysfunction (LVDD), contribute to an increased risk of heart failure (HF). The aim of this study was to determine the relationship between the occurrence of LVDD and ED with CV risk assessed by the Systematic Coronary Risk Evaluation2 (SCORE2) algorithm and HF. Methods: In the period from November 2019 to May 2022, a cross-sectional study that included 178 middle-aged adults was conducted. Transthoracic echocardiography (TTE) was used to assess left ventricular (LV) diastolic and systolic function. ED was assessed using the plasma values of asymmetric dimethylarginine (ADMA) and was determined using the ELISA method. Results: The majority of subjects with LVDD grades 2 and 3 had high/very high SCORE2, developed HF and all were taking medication (p < 0.001). They also had significantly lowest plasma ADMA values (p < 0.001). We found that the reduction of ADMA concentration is influenced by certain groups of drugs, or more significantly, by their combinations (p < 0.001). Conclusions: In our study, we confirmed a positive correlation between LVDD, HF and SCORE2 severity. The results showed a negative correlation between the biomarkers of ED, LVDD severity, HF, and SCORE2, which we believe is due to medication effects.
Collapse
Affiliation(s)
- Livija Sušić
- Department of Specialist-Consultative Health Care, Health Center of Osijek-Baranja County, 31000 Osijek, Croatia
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
| | - Lana Maričić
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
- Department of Cardiology, University Hospital Center Osijek, 31000 Osijek, Croatia
| | - Ines Šahinović
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
- Department of Clinical Laboratory Diagnostics, University Hospital Center Osijek, 31000 Osijek, Croatia
| | - Kristina Kralik
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
| | - Lucija Klobučar
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
- Department of Cardiology, University Hospital Center Osijek, 31000 Osijek, Croatia
| | - Mateja Ćosić
- Department of Specialist-Consultative Health Care, Health Center of Osijek-Baranja County, 31000 Osijek, Croatia
| | - Tihomir Sušić
- The Information Institute Osijek, 31000 Osijek, Croatia
| | - Josip Vincelj
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
- NovaMed Health Center Zagreb, 10000 Zagreb, Croatia
| | - Antonio Burić
- Department of Radiology, Health Center of Osijek-Baranja County, 31000 Osijek, Croatia
| | - Marko Burić
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
| | - Matea Lukić
- Faculty of Medicine, University “Josip Juraj Strossmayer”, 31000 Osijek, Croatia
| |
Collapse
|
2
|
Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 2021; 20:218. [PMID: 34740359 PMCID: PMC8571004 DOI: 10.1186/s12933-021-01408-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 10/25/2021] [Indexed: 02/06/2023] Open
Abstract
Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the proposed mechanistic bases, explaining the myocardial damage induced by diabetes-related stressors and other risk factors, i.e., cardiomyopathy in type 2 diabetes. We highlight the complex pathology of individuals with type 2 diabetes, including the relationship with chronic kidney disease, metabolic alterations, and heart failure. We also discuss the current criteria used for heart failure diagnosis and the gold standard screening tools for individuals with type 2 diabetes. Currently approved pharmacological therapies with primary use in type 2 diabetes and heart failure, and the treatment-guiding role of NT-proBNP are also presented. Finally, the influence of the presence of type 2 diabetes as well as heart failure on COVID-19 severity is briefly discussed.
Collapse
Affiliation(s)
- Antonio Ceriello
- IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138 Milan, Italy
| | - Doina Catrinoiu
- Faculty of Medicine, Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Ovidius University of Constanta, Constanta, Romania
| | - Chanchal Chandramouli
- Duke-NUS Medical School, Singapore, Singapore
- National Heart Research Institute, National Heart Centre, Singapore, Singapore
| | - Francesco Cosentino
- Unit of Cardiology, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
| | | | - Baruch Itzhak
- Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel
| | - Nebojsa Malić Lalic
- School of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University of Belgrade, Belgrade, Serbia
| | | | - Oliver Schnell
- Forschergruppe Diabetes e. V. at Helmholtz Centre Munich GmbH, Munich, Germany
| | - Petar M. Seferović
- School of Medicine, University of Belgrade, Belgrade University Medical Center, Belgrade, Serbia
| | - Paul Valensi
- Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, AP-HP, CRNH-IdF, CINFO, Paris 13 University, Bondy, France
| | - Eberhard Standl
- Forschergruppe Diabetes e. V. at Helmholtz Centre Munich GmbH, Munich, Germany
| | - the D&CVD EASD Study Group
- IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138 Milan, Italy
- Faculty of Medicine, Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Ovidius University of Constanta, Constanta, Romania
- Duke-NUS Medical School, Singapore, Singapore
- National Heart Research Institute, National Heart Centre, Singapore, Singapore
- Unit of Cardiology, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
- Sciarc GmbH, Baierbrunn, Germany
- Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel
- School of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University of Belgrade, Belgrade, Serbia
- Forschergruppe Diabetes e. V. at Helmholtz Centre Munich GmbH, Munich, Germany
- School of Medicine, University of Belgrade, Belgrade University Medical Center, Belgrade, Serbia
- Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, AP-HP, CRNH-IdF, CINFO, Paris 13 University, Bondy, France
| |
Collapse
|
3
|
Bidaut A, Hubert A, Charton M, Paven E, Leclercq C, Galli E, Donal E. One year prognostic value of B-lines in dyspnoeic patients. ESC Heart Fail 2021; 8:1759-1766. [PMID: 33704921 PMCID: PMC8120353 DOI: 10.1002/ehf2.12739] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 03/21/2020] [Accepted: 04/15/2020] [Indexed: 11/24/2022] Open
Affiliation(s)
- Auriane Bidaut
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Arnaud Hubert
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Marion Charton
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Elise Paven
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Christophe Leclercq
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Elena Galli
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| | - Erwan Donal
- Service de Cardiologie et Maladies Vasculaires et CIC-IT 1414, CHU Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.,LTSI, Université de Rennes 1, Rennes, France.,INSERM, Rennes, France
| |
Collapse
|
4
|
Lai MY, Kan WC, Huang YT, Chen J, Shiao CC. The Predictivity of N-Terminal Pro b-Type Natriuretic Peptide for All-Cause Mortality in Various Follow-Up Periods among Heart Failure Patients. J Clin Med 2019; 8:jcm8030357. [PMID: 30871208 PMCID: PMC6463167 DOI: 10.3390/jcm8030357] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2019] [Revised: 03/02/2019] [Accepted: 03/09/2019] [Indexed: 02/08/2023] Open
Abstract
Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) is an excellent prognostic–predictive tool in heart failure (HF) patients, but its plasma level changes following therapy. The comparison of prognosis–predictivity of a single measurement of plasma NT-pro BNP in different follow-up periods in acute HF patients has been less studied. This study aimed to evaluate whether the association between initial plasma NT-proBNP levels and all-cause mortality would decrease along with an increased follow-up period in patients with acute HF. The retrospective study was carried out, enrolling adult patients with hospitalization-requiring acute HF who fulfilled the predefined criteria from January 1, 2011, to December 31, 2013. We evaluated the independent predictors of 12-month mortality, and subsequently compared the predictivity of NT-proBNP level at initial presentation for 1-, 3-, 6-, 9- and 12-month mortality. In total, 269 patients (mean age, 74.45 ± 13.59 years; female, 53.9%) were enrolled. The independent predictors of 12-month mortality included higher “Charlson Comorbidity Index” (adjusted hazard ratio (aHR) = 1.22; 95% confidence interval (CI), 1.10–1.34), increased “age” (aHR = 1.07; 95% CI, 1.04–1.10), “administration of vasopressor” (aHR = 3.43; 95% CI, 1.76–6.71), “underwent cardiopulmonary resuscitation” (aHR = 4.59; 95% CI, 1.76–6.71), and without “angiotensin-converting enzyme inhibitors/angiotensin receptor blocker” (aHR = 0.41; 95% CI, 1.86–11.31) (all p <0.001). “Plasma NT-pro BNP level ≧11,755 ng/L” was demonstrated as an independent predictor in 1-month (aHR = 2.37; 95% CI, 1.10–5.11; p = 0.028) and 3-month mortality (aHR = 1.98; 95% CI, 1.02–3.86; p = 0.045) but not in more extended follow-up. The outcome predictivity of plasma NT-proBNP levels diminished in a longer follow-up period in hospitalized acute HF patients. In conclusion, these findings remind physicians to act with caution when using a single plasma level of NT-proBNP to predict patient outcomes with a longer follow-up period.
Collapse
Affiliation(s)
- Min-Yu Lai
- Department of Nursing, Saint Mary's Hospital Luodong, Luodong, Yilan 26546, Taiwan.
| | - Wei-Chih Kan
- Department of Nephrology, Department of Internal medicine, Chi Mei Medical Center, Yongkang District, Tainan City 710, Taiwan.
- Department of Biological Science and Technology, Chung Hwa University of Medical Technology, Rende District, Tainan City 717, Taiwan.
| | - Ya-Ting Huang
- Department of Nursing, Saint Mary's Hospital Luodong, Luodong, Yilan 26546, Taiwan.
| | - John Chen
- Division of Cardiovascular Medicine, Department of Internal Medicine, Saint Mary's Hospital Luodong, Luodong, Yilan 26546, Taiwan.
| | - Chih-Chung Shiao
- Division of Nephrology, Department of Internal Medicine, Saint Mary's Hospital Luodong, Luodong, Yilan 26546, Taiwan.
- Saint Mary's Junior College of Medicine, Nursing and Management, Sanxing Township, Yilan County 266, Taiwan.
| |
Collapse
|
5
|
Randomized comparison of sevoflurane versus propofol-remifentanil on the cardioprotective effects in elderly patients with coronary heart disease. BMC Anesthesiol 2017; 17:104. [PMID: 28800722 PMCID: PMC5553920 DOI: 10.1186/s12871-017-0397-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 08/06/2017] [Indexed: 01/22/2023] Open
Abstract
Background It is skeptical about cardioprotective property of sevoflurane in patients undergoing noncardiac surgery, especially in the elderly patients with coronary heart disease. We hypothesized that long duration of sevoflurane inhalation in noncardiac surgery could ameliorate myocardial damage in such patients. Methods This was a randomized, prospective study. One hundred twenty-one elderly patients with coronary heart disease were randomly allocated into two groups. Maintenance of anesthesia was achieved by sevoflurane inhalation (Group S) or propofol-remifentanil respectively (Group PR). Serum cardiac troponin I (cTnI) and brain natriuretic peptide (BNP) were measured before anesthesia induction (T0), 8 h (T1) and 24 h (T2) after anesthesia respectively. The perioperative cardiac output, complications and postoperative 3-month follow-up from end of surgery were recorded. Results Between the two groups, there were no statistical differences in the values of cTnI and BNP during the study. However, The area under the curve of cTnI values over 24 h after operation was less in Group S. Group PR had lower cardiac output and consumed more amount of phenylephrine during the study (P < 0.05). Conclusions Compared with the group PR, sevoflurane had no benefit in the myocardial protection for the elderly patients with CHD. However, Sevoflurane showed advantage in maintaining hemodynamic stability during the operative period. Trial registration Chinese Clinical Trial Registry, ChiCTR-IPR-16008871, 21 July 2016.
Collapse
|